SEC-sourced researchBeta
ADPT
Adaptive Biotechnologies Corp
Company comparison ↗
Data passport
- CIK
- 0001478320
- Exchange
- Nasdaq
- Business activity
- Biological Products, (No Diagnostic Substances) · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Nov 13, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 170,276,000.0000 | Feb 26, 2026 |
| December 2024 | 178,957,000.0000 | Feb 26, 2026 |
| December 2025 | 276,976,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 276,976,000.0000 | -59,499,000.0000 | -45,986,000.0000 | 512,736,000.0000 | 287,735,000.0000 | Feb 26, 2026 |
| December 2024 | 178,957,000.0000 | -159,492,000.0000 | -95,212,000.0000 | 539,376,000.0000 | 336,891,000.0000 | Feb 26, 2026 |
| December 2023 | 170,276,000.0000 | -225,250,000.0000 | -156,324,000.0000 | — | — | Feb 26, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
54/100
Profitability7
Growth100
Balance sheet44
Cash generation17
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $276.98M | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $178.96M | Jan 1, 2024 – Dec 31, 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$59.5M | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$45.99M | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $512.74M | Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $287.74M | Dec 31, 2025 | Feb 26, 2026 | 10-K |
New filings
- 4ADPT · Adaptive Biotechnologies CorpNov 13, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpNov 13, 2026 · Other
- 144ADPT · Adaptive Biotechnologies CorpNov 12, 2026 · Other
- 144ADPT · Adaptive Biotechnologies CorpNov 12, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpNov 12, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpNov 10, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpNov 6, 2026 · Other
- 10-QADPT · Adaptive Biotechnologies CorpNov 4, 2026 · Periodic
- 8-KADPT · Adaptive Biotechnologies CorpNov 4, 2026 · Current event
- 4ADPT · Adaptive Biotechnologies CorpNov 3, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 29, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 26, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 21, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 16, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 13, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 8, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 8, 2026 · Other
- 144ADPT · Adaptive Biotechnologies CorpOct 6, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 5, 2026 · Other
- 4ADPT · Adaptive Biotechnologies CorpOct 5, 2026 · Other